Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026

Same author

Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features.

Nature cancer·2025

Same author

Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction.

Blood advances·2025

Same author

Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia - the CONS.

Haematologica·2025

Same author

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

British journal of haematology·2024

Same author

Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study.

Bone marrow transplantation·2024

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Optimal induction and post-remission therapy for AML in first remission.

¹Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa, Israel. rowe@jimmy.harvard.edu

Hematology. American Society of Hematology. Education Program

|December 17, 2009

Summary

Acute myeloid leukemia (AML) affects 300,000 annually, with outcomes poor for older adults despite treatment advances. New therapies are urgently needed to improve cure rates for this growing patient population.

Related Experiment Videos

Last Updated: Jun 17, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Area of Science:

Hematology
Oncology
Internal Medicine

Background:

Acute myeloid leukemia (AML) diagnosis impacts approximately 300,000 individuals globally each year.
The median age of AML patients is increasing, nearing 70 years, highlighting a growing challenge in geriatric oncology.
Despite decades of therapeutic progress, significant mortality persists, particularly among young adults and older individuals.

Purpose of the Study:

To review the current therapeutic landscape for acute myeloid leukemia (AML).
To highlight the challenges and unmet needs in treating older adults with AML.
To underscore the urgent requirement for novel therapeutic strategies in AML management.

Main Methods:

Review of existing literature on acute myeloid leukemia (AML) treatment strategies.
Analysis of treatment outcomes based on patient age, focusing on young adults and older adults.
Evaluation of the efficacy of current chemotherapy and allogeneic transplantation protocols.

Main Results:

Complete remission rates are achievable in most young AML patients, but long-term survival remains a challenge.
Treatment outcomes for older adults with AML are unsatisfactory, with low long-term survival rates despite remission induction.
Allogeneic transplantation offers improved outcomes by harnessing graft-versus-leukemia effects, but its applicability and success in older populations require further investigation.

Conclusions:

Current AML therapies, while advanced, show limited efficacy in achieving long-term cures, especially in older populations.
Intensive chemotherapy and allogeneic transplantation represent current standards but necessitate further optimization.
The development and validation of novel, targeted agents are critical for improving AML treatment and achieving better cure rates, particularly for elderly patients.